Are they as beneficial to manufacturers as they seem?
By Joana Fernandes & Ashkay Kumar
What are the research aims?
Products that are being reviewed by the BeNeLuxA and FiNoSe joint initiatives often generate a lot of media attention and interest for those in the pharma world. But what do these initiatives actually entail, and are manufacturers more likely to achieve a positive price or access outcome through these innovative routes?